Frequency Distribution of CYP2C9 and VKORC1 Mutations among Bulgarian Patients and their Importance for Anticoagulant Therapy

被引:0
|
作者
Velizarova, Milena [1 ,2 ]
Abedinov, Philip [3 ]
Svinarov, Dobrin [1 ,2 ]
Nikolov, Valentin [4 ]
Hristova, Julieta [1 ,2 ]
机构
[1] Med Univ Sofia, Fac Med, Dept Clin Lab, Sofia, Bulgaria
[2] Alexander Univ Hosp, Sofia, Bulgaria
[3] St Ekaterina Univ Hosp, Sofia, Bulgaria
[4] SGP Bio Dynam Ltd, Sofia, Bulgaria
关键词
CYP2C9; oral anticoagulants; pharmacogenetics; VKORC1; GENETIC POLYMORPHISMS; PRESCRIBING ERRORS; WARFARIN; PREVALENCE; REQUIREMENT; GENOTYPE;
D O I
10.7754/Clin.Lab.2022.220213
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Background: Genetic polymorphisms of CYP2C9 and VKORC1 play a major role in pharmacokinetics and pharmacodynamics of coumarin anticoagulants. The purpose of our study was to assess the relative frequency of the above mutations in Bulgarian population in order to predict bleeding tendencies and precisely manage the anticoagulant therapy during the postoperative period after cardiac surgery with extracorporeal circulation. Methods: Genomic DNA samples from 200 Bulgarian patients subjected to cardiac surgery with extracorporeal circulation were analyzed for VKORC1 1639G>A and CYP2C9*2&*3 polymorphisms by real-time polymerase chain reaction (PCR), then allele frequencies of various genotypes were calculated by Hardy-Weinberg Equilibrium. Results: Median patients' age was 63.9 +/- 10.8 years; 66.5% were male. Median BMI was 28.6 +/- 5.4 kg/m 2 . Genotype distribution for CYP2C9 was *1/*1 - 51%, *1/*2 - 21%, *1/*3 - 13.5%, *2/*3 - 4%, *3/*3 - 2%, and *2/*2 1.5%. The calculated frequency of CYP2C9*1 allele was 74.25%, CYP2C9*2 allele was 13%, and CYP2C9*3 allele was 12.75%, and all allelic frequencies were in Hardy-Weinberg equilibrium (p-value = 0.358). The major VKORC1 genotype was G/A - 47%, followed by G/G - 35.5% and A/A - 17.5%). Based on Hardy-Weinberg Equilibrium, there was no significant difference between observed and expected frequencies (X - -3.779), presumably as a result of the homogeneity in the population. Conclusions: Analysis of the data obtained in the course of the study suggested that identification of homozygous carriers of VKORC1-1639 G>A (rs9923231) in Bulgarians may be useful in developing recommendations for personalized therapy. On the contrary, homozygous carriers of CYP2C9*2 or *3, included only 4.5% of the studied patients, thus indicating that this group would benefit less from dosing algorithms. Our results demonstrated good agreement with the results obtained in other studies conducted in the Caucasian population.
引用
收藏
页码:2527 / 2532
页数:6
相关论文
共 50 条
  • [21] Frequency of CYP2C9 and VKORC1 Gene Polymorphisms and Their Influence on Warfarin Dose in Egyptian Pediatric Patients
    Mennat-Allah Kamal El-Din
    Marwa Salah Farhan
    Randa Ibrahim El Shiha
    Rania Mohammed Helmy El-Kaffas
    Somaia Mohammed Mousa
    Pediatric Drugs, 2014, 16 : 337 - 341
  • [22] Resequencing of VKORC1, CYP2C9 and CYP4F2 genes in Italian patients requiring extreme low and high warfarin doses
    Di Fusco, Davide
    Ciccacci, Cinzia
    Rufini, Sara
    Forte, Vittorio
    Novelli, Giuseppe
    Borgiani, Paola
    THROMBOSIS RESEARCH, 2013, 132 (01) : 123 - 126
  • [23] The Influence of CYP2C9 and VKORC1 Gene Polymorphisms on the Response to Warfarin in Egyptians
    Bedewy, Ahmed M. L.
    Showeta, Salah
    Mostafa, Mostafa Hasan
    Kandil, Lamia Saeed
    INDIAN JOURNAL OF HEMATOLOGY AND BLOOD TRANSFUSION, 2018, 34 (02) : 328 - 336
  • [24] Clinical Significance of Combined CYP2C9 and VKORC1 Genotypes in Japanese Patients Requiring Warfarin
    Miyagata, You
    Nakai, Kenji
    Sugiyama, Yoshiki
    INTERNATIONAL HEART JOURNAL, 2011, 52 (01) : 44 - 49
  • [25] Effect of Genetic Variants, Especially CYP2C9 and VKORC1, on the Pharmacology of Warfarin
    Fung, Erik
    Patsopoulos, Nikolaos A.
    Belknap, Steven M.
    O'Rourke, Daniel J.
    Robb, John F.
    Anderson, Jeffrey L.
    Shworak, Nicholas W.
    Moore, Jason H.
    SEMINARS IN THROMBOSIS AND HEMOSTASIS, 2012, 38 (08) : 893 - 904
  • [26] Effect of CYP2C9 and VKORC1 genetic variations on warfarin dose requirements in Indian patients
    Natarajan, Sripriya
    Ponde, Chandrashekhar K.
    Rajani, Rajesh M.
    Jijina, Farah
    Gursahani, Roopkumar
    Dhairyawan, Pradnya P.
    Ashavaid, Tester F.
    PHARMACOLOGICAL REPORTS, 2013, 65 (05) : 1375 - 1382
  • [27] Genotyping of CYP2C9 and VKORC1 in the Arabic Population of Al-Ahsa, Saudi Arabia
    Alzahrani, Abdullah M.
    Ragia, Georgia
    Hanieh, Hamza
    Manolopoulos, Vangelis G.
    BIOMED RESEARCH INTERNATIONAL, 2013, 2013
  • [28] Contribution of VKORC1 and CYP2C9 polymorphisms in the interethnic variability of warfarin dose in Malaysian populations
    Gan, Gin Gin
    Phipps, Maude E.
    Lee, Michael M. T.
    Lu, Liang S.
    Subramaniam, Rajallectchumy Y.
    Bee, Ping C.
    Chang, Sean H.
    ANNALS OF HEMATOLOGY, 2011, 90 (06) : 635 - 641
  • [29] The VKORC1 and CYP2C9 gene variants as pharmacogenetic factors in acenocoumarol therapy in Serbian patients - consideration of hypersensitivity and resistance
    Rakicevic, Ljiljana
    Kovac, Mirjana
    Radojkovic, Dragica
    Radojkovic, Milica
    SRPSKI ARHIV ZA CELOKUPNO LEKARSTVO, 2022, 150 (3-4) : 156 - 162
  • [30] Ability of VKORC1 and CYP2C9 to predict therapeutic warfarin dose during the initial weeks of therapy
    Ferder, N. S.
    Eby, C. S.
    Deych, E.
    Harris, J. K.
    Ridker, P. M.
    Milligan, P. E.
    Goldhaber, S. Z.
    King, C. R.
    Giri, T.
    McLeod, H. L.
    Glynn, R. J.
    Gage, B. F.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2010, 8 (01) : 95 - 100